Observational Study of the Changes in Skin Thickness Among Children with Atopic Dermatitis Treated with Topical Mometasone Furoate 0.1% Cream

Abstract

Background: Atopic dermatitis (AD) affects up to 20% of children worldwide and, as of now, it has no cure. The primary treatment for AD in children involves the use of topical corticosteroids. Objectives: Our objective was to evaluate the potential for skin atrophy caused by the application of mometasone furoate 0.1% cream in children with moderate to severe AD. Methods: This study was a single-center, prospective cohort study involving 22 children aged 6-12 years with moderate to severe AD. The children applied topical mometasone furoate 0.1% cream for 6 weeks in a non-occlusive manner. We conducted dermoscopic and ultrasonographic assessments of skin atrophy at 0, 2, and 6 weeks into the treatment. Results: All patients exhibited an improvement in skin erythema. At the beginning of the study, 91% of the patients had mild to moderate erythema, while 9.1% had severe erythema. After 6 weeks of using topical mometasone, 27.3% had mild erythema, and 72.7% had completely resolved erythema (P